Introduction
============

Type 2 diabetes (T2DM) is a long-term metabolic disorder. At the beginning of this disorder, most T2DM patients are in an insulin-resistant state, especially in obese individuals.[@b1-dmso-12-139]--[@b3-dmso-12-139] Long-term compensatory upregulation of insulin leads to an impairment of β-cell function.[@b4-dmso-12-139] Insulin resistance and obesity are found in a metabolically unhealthy condition that can lead to prediabetes or even diabetes.[@b5-dmso-12-139] Epidemiological studies have reported that obesity is an important factor of insulin resistance,[@b6-dmso-12-139],[@b7-dmso-12-139] in which free fatty acids (FFAs) may exert an assignable effect.

FFAs are intermediate products of fat mobilization, which result from lipolysis and the breakdown of triglycerides (TGs).[@b8-dmso-12-139] The FFAs are transported to the mitochondria and broken down into CO~2~ and H~2~O through β-oxidation, resulting in the production of ATP. In an endocrine process, the levels of FFAs are decreased by insulin, in a process involving inhibition of lipolysis. Elevated FFA levels can also lead to insulin resistance and other metabolic disorders.[@b9-dmso-12-139],[@b10-dmso-12-139] Previous studies have reported that long-term FFA-associated insulin resistance was associated with T2DM or other metabolic diseases.[@b11-dmso-12-139],[@b12-dmso-12-139] Knowledge of FFA functional mechanisms can therefore provide a basis for preventing and treating diabetes.[@b13-dmso-12-139]

Studies have reported correlations between FFA levels, insulin resistance, and T2DM,[@b7-dmso-12-139],[@b11-dmso-12-139],[@b14-dmso-12-139] but the detailed pathological processes involving FFAs in T2DM are not clear. Some reports have suggested that high levels of FFAs impair islet β-cell functioning,[@b15-dmso-12-139] while other reports have suggested that high FFA levels lead to insulin resistance by inhibiting the insulin sensitivity of target cells. To characterize the actual effects of FFAs on islet functions and to determine how FFA levels might alter islet β-cell functions, we performed a cross-sectional study involving a large health checkup population in China.

Methods
=======

Study participants
------------------

In total, using random cluster sampling methods, 8,752 participants, aged 20--80 years, from the coastal areas of Shandong Province, China, were examined, and 7,890 (4,900 females and 2,990 males) individuals were selected. The sampling was conducted from August 2015 to December 2017. We collected the blood samples and other basic information during the investigation. The exclusion criteria were missing data samples, occurrence of diabetes in patients, prior drug use that would impair β-cell functions or reduce blood lipids, and/or occurrence of liver disease or digestive diseases that would influence absorption, transport, and decomposition of FFAs. In total, 1,938 subjects were excluded. Finally, there were 5,952 individuals in the final analyses. All the individuals signed the informed consent, and the study protocol adhered to the Declaration of Helsinki. The study protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Qingdao University (QDFYLLWY-201506 number 15--27).

According to Chinese obesity reference standards, the individuals were divided into two groups according to the body mass index (BMI): the nonobese group (BMI \<24 kg/m^2^), and the obese group (BMI ≥24 kg/m^2^). In subgroup analyses, on the basis of the previous grouping, each group was further randomized into the prediabetes group and group with no glucose impairment based on the criteria of the American Diabetes Association (ADA):[@b16-dmso-12-139] HbA1c threshold \<5.7%, and HbA1c threshold 5.7%--6.4%, respectively.

Biochemical measurements
------------------------

We collected blood samples after 8 hours of fasting, prior to the laboratory tests. HbA1c was measured by HPLC (Bio-Rad Variant II HbA1c analyzer; Bio-Rad, Hercules, CA, USA). Serum insulin was measured by an electrochemiluminescence method (Cobas e 601; Roche Diagnosis, Mannheim, Germany). Serum samples were assayed for levels of thyroid stimulating hormone (TSH) through electrochemiluminescence using the Cobas e411 automated immunoassay platform (Roche Diagnostics GmbH, Mannheim, Germany). Plasma glucose (glucose oxidase method), FFA (enzyme cycling method), serum uric acid (uricase-phenol--amino-phenazone/*N*-ethyl-*N*-(2-hydroxy-3-sulfopropyl)-3-methylaniline \[PAP/TOOS\] method), serum total cholesterol (cholesterol oxidase/peroxidase aminophenazone \[CHOD-PAP\] method), serum high-density lipoprotein cholesterol (HDL-C) \[International Reagents Corp HDL-C assay method\]), serum low-density lipoprotein cholesterol (LDL-C) (catalase LDL-C assay method), serum TGs (glycerol lipase oxidase \--peroxidase antiperoxidase method), as well as the enzymes aspartate aminotransferase, alanine aminotransferase, ALP (colorimetric analysis) were measured on a Hitachi 7600±020 instrument (Hitachi, Tokyo, Japan).

In order to evaluate the functions of β-cells and the degree of insulin resistance, we used the homeostasis model assessment for insulin resistance (HOMA-IR) and β-cell function (HOMA-β) models.[@b17-dmso-12-139]

The HOMA-IR evaluates insulin resistance as follows: $$\text{HOMA-IR} = \text{fasting~insulin}\left( \text{FINS} \right)\left( {\text{mIU}/\text{mL}} \right) \times \text{fasting~glucose}\left( \text{mmol/L} \right)\text{/22}.\text{5}$$

The HOMA-β estimates pancreatic β-cell function as follows: $$\text{HOMA-}\beta = 20 \times \text{FINS}\left( {\text{mIU}/\text{mL}} \right)/\left( {\text{fasting~glucose}\left( {\text{mmol}/L} \right)–3.5} \right)$$

Statistical analyses
--------------------

The R software program, version 3.2.2 (<http://www.Rproject.org>) and the SPSS program, version 23.0 (IBM Corporation, Armonk, NY, USA) were used for statistical analyses. The Kolmogorov--Smirnov *Z* tests were used to determine whether the data were normally distributed. We used the mean ± SD or median (25th percentile, 75th percentile) as a description of the data. Differences between two groups were compared by independent two-tailed Student's *t*-tests for normally distributed data or Mann--Whitney *U* tests for abnormally distributed data. One-way ANOVA was performed to estimate the influencing factors of pancreatic islet cell functions.

We further explored the nonlinear relationship between FFAs and pancreatic islet cell function by using generalized smoothing splines with knot locations generated automatically in generalized additive models by the R package software. We also attempted to determine the turning point of the relationships between FFAs and pancreatic islet cell function. The turning point of FFA levels was determined by using trial and error methods. We performed linear regression analyses to estimate the relationship between FFAs and HOMA-IR before and after the turning point in the different groups. A *P*-value (two-tailed) \<0.05 was considered statistically significant.

Results
=======

Higher levels of FFAs, HOMA-IR, and HOMA-β were detected in obese individuals
-----------------------------------------------------------------------------

As shown in [Table 1](#t1-dmso-12-139){ref-type="table"}, there were no significant differences in sex, age, TSH levels, and the concentrations of uric acid. However, the characteristics of glycometabolism and lipid metabolism were significantly different. Compared to the nonobese group (BMI \<24 kg/m^2^), FFA concentrations were slightly higher in the obese group (BMI ≥24 kg/m^2^) (0.45±0.23 vs 0.47±0.22, *P*=0.012). Additionally, TGs, total cholesterol,[@b18-dmso-12-139] and LDL-C levels were higher (*P*\<0.001) and HDL-C levels were lower in the obese group (*P*\<0.001). In the obese group, several glycometabolism-related parameters were higher, including FINS (12.89±8.67 vs 8.95±6.79 P\<0.001) and fasting plasma glucose (FPG) (5.91±1.21 vs 5.62±0.99, *P*\<0.05). HOMA-IR and HOMA-β, the indexes for evaluating islet cell functions, were significantly higher in the obese group (1.93±0.65 vs 1.61±0.58, *P*\<0.001; 108.9±61.98 vs 94.21±55.75, *P*\<0.001) than in the nonobese group. According to these results, multiple indexes, such as FFA levels, HOMA-IR, and HOMA-β, were increased in nondiabetic obese individuals, but the correlations of these parameters with HOMA-IR/HOMA-β are still unknown.

High FFA levels maybe an important risk factor for insulin resistance in obese individuals
------------------------------------------------------------------------------------------

One-way ANOVA was performed to determine the influence of HOMA-IR/HOMA-β among lipid metabolism indexes. HOMA-IR and HOMA-β were regarded as dependent variables, and, the waist-to-hip ratio (WHR), TC, TG, LDL-C, HDL-C, and FFAs were regarded as independent variables. Four items, including TC, TG, LDL-C, and HDL-C, were factors influencing HOMA-IR in the nonobese group, and five items, including WHR, TG, LDL-C, HDL-C, and FFA, were factors influencing the same in the obese group ([Table 2](#t2-dmso-12-139){ref-type="table"}). Additionally, HDL-C, LDL-C, and TC in the nonobese group, as well as HDL-C, LDL-C, TC, and TG in the obese group, were the factors influencing HOMA-β ([Table 2](#t2-dmso-12-139){ref-type="table"}). No association was observed between FFAs and HOMA-β in both cohorts. Lipid metabolism indexes such as TC, LDL-C, and HDL-C were the basic risk factors for pancreatic islet cell function, while FFA levels may be an important factor for insulin resistance in obesity.

Insulin resistance was enhanced at FFA concentrations \>0.54 mmol/L and \>0.61 mmol/L in the two groups
-------------------------------------------------------------------------------------------------------

In order to analyze the correlation between FFA concentration and HOMA-IR, we analyzed the relationship after adjusting for TC, TG, HDL-C, and LDL-C. The effects of FFAs on HOMA-IR values in both cohorts are shown in [Figure 1](#f1-dmso-12-139){ref-type="fig"}. Smoothing splines suggested that the rate of increase of HOMA-IR value in the obese group ([Figure 1](#f1-dmso-12-139){ref-type="fig"}, Group 2) was faster than that in the nonobese group ([Figure 1](#f1-dmso-12-139){ref-type="fig"}, Group 1). In the obese group, HOMA-IR showed a trend of smooth decrease with the FFA concentration of 0--0.61 mmol/L and then became enhanced. From the FFA concentration of 0.61 mmol/L, the HOMA-IR increased linearly with increasing FFA levels, after adjusting for TC, TG, HDL-C, and LDL-C. The linear regression coefficients of FFAs above 0.61 mmol/L were 1.58 (95% CI: 0.29, 2.87, *P*=0.0161) ([Table 3](#t3-dmso-12-139){ref-type="table"}). In the nonobese group, HOMA-IR showed a decreasing trend with FFA concentrations of 0--0.54 mmol/L and an increasing trend beyond 0.54 mmol/L, after adjusting for TC, TG, HDL- C, and LDL-C. The linear regression coefficients of FFAs \<0.54 mmol/L were −0.9 (95% CI: −1.59,−0.21, *P*=0.0111) and 0.9 (95% CI: 0.25,1.55, *P*=0.0069) for FFAs ≥0.54 ([Table 3](#t3-dmso-12-139){ref-type="table"}). Additionally, the association between HOMA-β and FFAs was also analyzed in both cohorts, and the results are shown in [Figure S1](#SD1-dmso-12-139){ref-type="supplementary-material"}. There were no significant correlations between FFA concentrations and HOMA-β, but the trend of HOMA-β being influenced by FFA levels was higher in the obese group.

High FFA levels were identified as a risk factor for prediabetes in obese individuals
-------------------------------------------------------------------------------------

We performed additional analyses to determine the risk factors for prediabetes. Some prospective studies demonstrated that HbA1c ≥5.7% was a strong predictor of subsequent diabetes.[@b16-dmso-12-139],[@b19-dmso-12-139],[@b44-dmso-12-139] In order to analyze the predictive ability of lipid metabolism indexes on prediabetes, we divided all participants into four subgroups according to BMI and HbA1c levels as follows: nonobese control group (BMI \<24 kg/m^2^ and HbA1c \<5.7%), nonobese prediabetes group (BMI \<24 kg/m^2^ and 5.7% ≤ HbA1c \<6.5%), obese control group (BMI ≥24 kg/m^2^ and HbA1c \<5.7%), and obese prediabetes group (BMI ≥24 kg/m^2^ and 5.7% ≤ HbA1c \<6.5%). The clinical data showed that several lipid metabolism indexes (except HDL-C) were higher in the prediabetes group than in the control group (*P*\<0.05) at the same BMI level ([Table 4](#t4-dmso-12-139){ref-type="table"}). There was no difference in FFA concentrations between the prediabetes and control groups in the nonobese individuals (*P*\>0.05). Logistic regression analyses indicated that six indexes were associated with the risk of prediabetes, including age, BMI, WHR, TC, TG, HDL-C, and LDL-C. After adjusting for age and BMI, the results showed that in the nonobese group, five factors were associated with prediabetes, including WHR, TC, TG, HDL-C, and LDL-C. In the obese group, besides the previously mentioned indexes, FFA concentration was another important risk factor for prediabetes.

Discussion
==========

According to our study, there were significant correlations between HOMA-IR/HOMA-β and multiple glucolipid metabolism indexes in obese individuals or in nonobese ones without diabetes. After adjusting for confounding factors such as HDL-C, LDL-C, TC, and TG, the results of HOMA-IR significantly increased with the increase of FFA concentrations, especially in the obese group. Interestingly, a U-shaped correlation was identified between FFA concentrations and HOMA-IR. The turning points of FFA levels were 0.54 mmol/L in the nonobese group and 0.61 mmol/L in the obese group. However, no correlation between FFA levels and HOMA-β was observed in the two groups. We further performed an analysis in the subgroups classified using BMI and HbA1c. Significantly higher FFA level was found in obese people with prediabetes status. These results indicated that high FFA levels may be a risk factor of prediabetes in obese individuals.

According to the literature,[@b20-dmso-12-139] insulin secretion is a complex process with various influencing factors, and FFA metabolism may exert double-sided effects on this course. FFA, at relatively low levels, functions as an energy source to provide ATP. Meanwhile, reduction of plasma FFA levels severely impairs glucose-induced release of insulin.[@b21-dmso-12-139] On the contrary, high concentrations of FFAs induce oxidative stress in tissues by producing increased levels of ROS and reactive nitrogen species,[@b22-dmso-12-139] which impair DNA and protein in tissues and may act as functionally signaling molecules in insulin resistance.[@b23-dmso-12-139],[@b24-dmso-12-139] In our research, we found that full utilization of FFAs or other lipids may impair insulin release in the descending segment of the curve, while in the ascending segment, increased levels of FFAs may contribute to the insulin-resistant state in both groups. Hence, this nonlinear relationship indicated the potential interaction between FFAs and insulin secretion. Interestingly, the turning point in the nonobese group showed up earlier than in the obese group, and the reasons were unclear. We posited a hypothesis that nonobese individuals may be more sensitive to FFA accumulation than obese ones.

Several studies have investigated the effect of FFAs on the process of glucose-induced insulin secretion.[@b21-dmso-12-139] Acutely elevated insulin secretion could be a compensating mechanism to offset the insulin resistance found under high FFA levels. Meanwhile, insulin functions not only in reducing blood sugar but also in the process of promoting fat synthesis and inhibiting fat breakdown.[@b5-dmso-12-139],[@b24-dmso-12-139] Gastaldelli[@b25-dmso-12-139] revealed that excess FFAs can be taken up by other organs (mainly liver), and that FFA oxidative metabolism is increased and not shifted toward glucose during insulin infusion. Roomp et al[@b26-dmso-12-139] and Johns et al[@b27-dmso-12-139] reported that the levels of FFAs have a modest negative correlation with insulin sensitivity. High levels of FFAs facilitate the process of insulin resistance, which is associated with the occurrence of T2DM.[@b1-dmso-12-139],[@b10-dmso-12-139],[@b28-dmso-12-139] A study had further shown that abundant FFAs lead to increased phosphorylation of serine/threonine on insulin receptors and insulin receptor substrate (IRS)-1, thereby activating the signaling inhibition function of protein kinase C.[@b10-dmso-12-139] Through downregulation of IkB-α, FFAs indirectly activate NF-kβ signaling, which results in inflammatory reactions and insulin resistance.[@b29-dmso-12-139],[@b30-dmso-12-139] Additionally, chronic inflammation in adipose tissue is one of the crucial reasons of obesity-related insulin resistance,[@b31-dmso-12-139],[@b32-dmso-12-139] and multiple factors such as STAT3, ROS, and TRL4 have been shown to be associated with tissue inflammation and insulin resistance, even β-cell dysfunction and apoptosis.[@b18-dmso-12-139],[@b33-dmso-12-139]--[@b38-dmso-12-139] High levels of FFAs can upregulate the expression of the P2X7 receptor, which plays an important role in oxidative stress and inflammatory responses.[@b39-dmso-12-139]

However, in our study, there was no significant correlation between FFAs and HOMA-β. However, high FFAs can increase insulin secretion acutely, not chronically.[@b40-dmso-12-139] Long-time oxidative stress can also damage islet cells.[@b41-dmso-12-139] We hypothesize that excessive FFAs will impair β-cells' function chronically.

Moreover, studies have demonstrated the correlation between FFA levels and prediabetes.[@b42-dmso-12-139],[@b43-dmso-12-139] Elevated FFA levels not only stimulate insulin secretion but also contribute to insulin resistance via induction of oxidative stress, endoplasmic reticulum stress, and inflammation of insulin-targeted cells. In addition, Toledo-Corral et al[@b42-dmso-12-139] found that prediabetic adolescents had higher levels of FFAs than normal adolescents. Insulin resistance caused by abundant FFAs can increase blood glucose levels and lead to prediabetes.[@b43-dmso-12-139]

We found that FFA levels may be a risk factor for prediabetes in obese individuals. Therefore, measuring and controlling plasma FFA levels in obese individuals is important for decreasing insulin resistance and controlling the progression to diabetes.

Conclusion
==========

In general, a U-shaped relationship between FFAs and HOMA-IR levels in nondiabetic individuals was revealed in our study, and there were differences when considering the BMI. The mechanism of this relationship needs many more investigations to interpret.

There are some limitations in our study. We cannot draw a definitive conclusion about causality in this cross-sectional design. It is better to repeat measurements of FFAs and HOMA-IR in experiments on animal models and in longitudinal studies, which will lend greater sensitivity to our findings.

Supplementary material
======================

###### 

Nonlinear relationship between FFA concentration and HOMA-β in the nonobese group (Group 1) and the obese group (Group 2).

**Notes:** After adjusting for HDL-C, LDL-C, TC, and TG, there was no significant correlation between FFA concentrations and HOMA-β.

**Abbreviations:** FFA, free fatty acid; HDL-C, high-density lipoprotein; HOMA-β, homeostasis model assessment of β-cell function; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglyceride.
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![Nonlinear relationship between FFA concentration and HOMA-IR in the nonobese group (Group 1) and the obese group (Group 2).\
**Note:** Results are after adjusting for HDL-C, LDL-C, TC, TG, and WHR.\
**Abbreviations:** FFA, free fatty acid; HDL-C, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.](dmso-12-139Fig1){#f1-dmso-12-139}

###### 

Clinical characteristics of the two groups

                        18.5kg/m^2^≤BMI\<24kg/m^2^, which means the BMI between 18.5 to 24kg/m^2^.   BMI ≥24 kg/m^2^         *P*-value
  --------------------- ---------------------------------------------------------------------------- ----------------------- -----------
                                                                                                                             
  N                     2,798                                                                        3,154                   
  Sex, n, male/female   951/1,847 (34%/66%)                                                          1,135/2,019 (36%/64%)   0.71
  Age, years            49±10                                                                        50±12                   0.672
  WHR                   0.85±0.07                                                                    0.90±0.06               \<0.001
  FPG, mmol/L           5.62±0.99                                                                    5.91±1.21               \<0.001
  FINS, μIU/mL          8.95±6.79                                                                    12.89±8.67              \<0.001
  HbA1c, %              5.57±0.74                                                                    5.72±1.39               0.008
  FFA, mmol/L           0.45±0.23                                                                    0.47±0.22               0.012
  TC, mmol/L            5.23±1.10                                                                    5.39±1.09               \<0.001
  TG, mmol/L            1.09±0.85                                                                    1.60±1.26               \<0.001
  LDL-C, mmol/L         2.94±0.92                                                                    3.14±0.88               \<0.001
  HDL-C, mmol/L         1.67±0.40                                                                    1.46±0.41               \<0.001
  TSH, μIU/mL           2.33±3.62                                                                    2.45±4.11               0.857
  UA, μmol/L            290.00±78.52                                                                 299.27±80.60            0.073
  HOMA-IR, %            1.61±0.58                                                                    1.93±0.65               \<0.001
  HOMA-β, %             94.21±55.75                                                                  108.9±61.98             \<0.001

**Note:** Data are presented as medians (25th percentile, 75th percentile) for skewed distribution variables.

**Abbreviations:** BMI, body mass index; FFA, free fatty acid; FINS, fasting insulin; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; TSH, thyroid stimulating hormone; UA, uric acid; WHR, waist-to-hip ratio.

###### 

Effects of lipid metabolism indexes on HOMA-IR and HOMA-β

                     HOMA-IR: b (95% CI)    *P*-value   HOMA-b: b (95% CI)     *P*-value
  ------------------ ---------------------- ----------- ---------------------- -----------
                                                                               
  BMI \<24 kg/m^2^                                                             
  HDL-C, mmol/L      −1.53 (−1.73, −1.33)   \<0.001     −6.3 (−13.37, −1.23)   \<0.001
  LDL-C, mmol/L      0.15 (0.05, 0.24)      0.0021      5.63 (1.59, 9.86)      \<0.001
  TC, mmol/L         0.38 (0.30, 0.45)      \<0.001     2.41 (1.28, 4.96)      \<0.001
  TG, mmol/L         0.23 (0.13, 0.34)      \<0.001     5.23 (1.37, 10.83)     0.0673
  FFA, mmol/L        0.16 (2.14, 2.46)      0.0905      2.18 (0.42, 5.83)      0.0519
  WHR                0.19 (1.07, 1.46)      0.0763      3.67 (1.26, 8.85)      0.1102
  BMI ≥24 kg/m^2^                                                              
  HDL-C, mmol/L      −1.88 (−2.13, 1.64)    \<0.001     −6.9 (−12.67, −1.78)   \<0.001
  LDL-C, mmol/L      0.17 (0.05, 0.29)      0.0048      4.86 (0.87, 7.59)      \<0.001
  TC, mmol/L         0.50 (0.40, 0.59)      \<0.001     1.73 (0.3, 5.41)       \<0.001
  TG, mmol/L         0.27 (0.19, 0.36)      \<0.001     4.35 (0.35, 8.35)      0.0331
  FFA, mmol/L        0.52 (0.05, 1.00)      0.0018      2.72 (0.89, 6.34)      0.1225
  WHR                0.25 (1.52, 4.97)      0.0002      4.21 (2.32, 7.63)      0.0814

**Note:** The effect of lipid metabolism indexes on HOMA-IR and HOMA-β using one-way ANOVA.

**Abbreviations:** BMI, body mass index; FFA, free fatty acid; HDL-C, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.

###### 

Linear regression model for FFA concentration (mmol/L) and HOMA-IR in the nonobese and obese groups

  FFA group, mmol/L           Crude[a](#tfn5-dmso-12-139){ref-type="table-fn"}   Model 1[b](#tfn6-dmso-12-139){ref-type="table-fn"}   Model 2[c](#tfn7-dmso-12-139){ref-type="table-fn"}   Model 3[d](#tfn8-dmso-12-139){ref-type="table-fn"}                                                        
  --------------------------- -------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------- -------- --------------------- --------
                                                                                                                                                                                                                                                                                                     
  Nonobese group                                                                                                                                                                                                                                                                                     
   \<0.54                     −0.61 (−1.35, 0.13)                                0.1069                                               −0.61 (−1.35, 0.13)                                  0.1069                                               −0.9 (−1.59, −0.21)   0.0111   −0.9 (−1.59, −0.21)   0.0111
   ≥0.54                      0.57 (−0.18, 1.33)                                 0.1369                                               0.58 (−0.18, 1.33)                                   0.1333                                               0.9 (0.25, 1.55)      0.0069   0.9 (0.25, 1.55)      0.0071
  Difference between strata   1.18 (−0.10, 2.46)                                 0.0706                                               1.19 (−0.09, 2.47)                                   0.0697                                               1.80 (0.65, 2.95)     0.0023   1.80 (0.64, 2.95)     0.0023
  Obese group                                                                                                                                                                                                                                                                                        
   \<0.61                     0.27 (−0.37, 0.91)                                 0.4019                                               0.27 (--.037, 0.9)                                   0.4152                                               0.17 (−0.42, 0.76)    0.5806   0.2 (−0.39, 0.78)     0.5094
   ≥0.61                      1.35 (−0.13, 2.83)                                 0.0732                                               1.2 (−0.27, 2.67)                                    0.1107                                               1.58 (0.29, 2.87)     0.0161   1.5 (0.18, 2.82)      0.0263
  Difference between strata   1.08 (−0.74, 2.90)                                 0.2467                                               0.94 (−0.88, 2.75)                                   0.3132                                               1.42 (−0.19, 3.02)    0.0834   1.30 (−0.33, 2.93)    0.1170

**Notes:**

No adjustment.

Adjustment for WHR.

Additional adjustment for HDL-C, LDL-C, TC, and TG.

Additional adjustment for HDL-C, LDL-C, TC, TG, and WHR. Linear regression analyses were conducted separately in the strata for the nonobese group and the obese group.

**Abbreviations:** β, regression coefficient; FFA, free fatty acid; HDL-C, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LD, low-density lipoprotein; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.

###### 

Clinical characteristics of subgroups of control subjects and prediabetes participants, stratified by HbA1c and BMI

                     18.5 kg/m^2^ £ BMI \<24 kg/m^2^                  BMI ≥24 kg/m^2^                                 
  ------------------ --------------------------------- -------------- ----------------- -------------- -------------- ---------
                                                                                                                      
  N                  1,736                             1,062                            1,952          1,202          
  Sex, male/female   590/1,146                         362/700        0.174             702/1,250      432/770        0.78
  Age, years         47.06±12.52                       54.20±12.40    \<0.001           49.78±10.67    54.95±10.50    \<0.001
  WHR                0.84±0.07                         0.86±0.07      \<0.001           0.89±0.06      0.91±0.06      \<0.001
  FPG, mmol/L        5.47±0.66                         5.69±0.75      \<0.001           5.61±0.84      5.95±0.85      \<0.001
  FINS, μIU/mL       8.31±6.93                         12.71±8.77     \<0.001           10.54±7.56     13.73±8.78     \<0.001
  TC, mmol/L         5.19±1.07                         5.43±1.13      \<0.001           5.39±1.07      5.46±1.09      0.088
  TG, mmol/L         1.03±0.71                         1.19±0.96      \<0.001           1.49±1.13      1.62±1.12      0.000
  LDL-C, mmol/L      2.85±0.89                         3.15±0.96      \<0.001           3.08±0.85      3.25±0.93      \<0.001
  HDL-C, mmol/L      1.70±0.40                         1.63±0.41      0.003             1.51±0.45      1.43±0.35      \<0.001
  TSH, μIU/mL        2.35±4.28                         2.23±2.07      0.611             2.56±4.86      2.44±3.56      0.525
  UA, μmol/L         274.01±77.15                      274.78±79.80   0.869             300.9±80.57    301.99±81.40   0.770
  FFA, mmol/L        0.46±0.22                         0.47±0.23      0.364             0.46±0.21      0.49±0.22      0.009
  HOMA-IR            1.08±0.52                         1.62±0.56      \<0.001           1.47±0.76      2.46±0.89      \<0.001
  HOMA-β             94.79±61.07                       123.9±69.43    \<0.001           117.41±58.59   164.86±70.30   \<0.001

**Note:** Data are presented as mean ± SD for skewed distribution variables.

**Abbreviations:** BMI, body mass index; FFA, free fatty acid; FINS, fasting insulin; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, triglyceride; TSH, thyroid stimulating hormone; UA, uric acid; WHR, waist-to-hip ratio.
